Japan to Cut Price of Alzheimer's Drug Lecanemab
Tokyo, July 10 (Jiji Press)--Japan is expected to lower the price of lecanemab, an Alzheimer's drug codeveloped by Japanese drugmaker Eisai Co. and Biogen Inc. of the United States, following a health ministry panel's report citing its low cost-effectiveness. Based on the assessment report, the ministry is expected to cut the official price of the drug by up to 15 pct from the current level...
Tomas Kauer - News Moderator 
Tokyo, July 10 (Jiji Press)--Japan is expected to lower the price of lecanemab, an Alzheimer's drug codeveloped by Japanese drugmaker Eisai Co. and Biogen Inc. of the United States, following a health ministry panel's report citing its low cost-effectiveness. Based on the assessment report, the ministry is expected to cut the official price of the drug by up to 15 pct from the current level...
